Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05217576 · ClinicalTrials.gov registry record · NA
NBM-200 Clinical Study in Blood Donation Setting
A NA study of Hemoglobin H, sponsored by OneBlood.
- Completed
- Registry status
- NA
- Development phase
- 387
- Enrollment target
- 3
- Study locations
NCT05217576: Completed NA study of Hemoglobin H, sponsored by OneBlood.
NCT05217576 is a NA study of Hemoglobin H that has completed, run by OneBlood. The registered enrollment target is 387 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05217576, a NA study of Hemoglobin H, has completed, sponsored by OneBlood.
- COMPLETED
- Registry status
- NA
- Development phase
- 387 participants
- Enrollment target
- 3
- Study locations
Study Summary
The NBM-200 is a portable Hemoglobin and oximetry monitor, based on occlusion spectroscopy technology, for non-invasive spot checking of hemoglobin (Hb), estimated Hematocrit (Hct), SpO2 and pulse rate. The NBM-200 includes a reusable ring-shaped sensor probe that fits on the patient's finger, and a portable desktop monitor that calculates and displays the measurement result. The sensor probe consists of a multi-wavelength optical measuring system and inflatable cuff employing pneumatic tissue manipulation. Blood flow in the finger can be briefly occluded and the resulting changes in its optical behavior are analyzed to provide accurate measurements of Hb.
Primary Outcome
The mean bias between the NBM-200 and HemoCue readings and the laboratory reference
Conditions Studied
Interventions
- DEVICE NBM-200
Study Locations (3)
Florida
- Palm Harbor Donor Center - Palm Harbor
- OneBlood St. Pete Main Donor Center - St. Petersburg
- Tampa- Dale Mabry OneBlood Donor Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2018-11-02 |
| Phase | NA |
What the finished NCT05217576 record still lists
NCT05217576 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Hemoglobin H appearing as the primary indexed condition, and to 1 intervention - of which NBM-200 is the first listed.
NCT05217576 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05217576 about?
NCT05217576 is a clinical study titled "NBM-200 Clinical Study in Blood Donation Setting". The NBM-200 is a portable Hemoglobin and oximetry monitor, based on occlusion spectroscopy technology, for non-invasive spot checking of hemoglobin (Hb), estimated Hematocrit (Hct), SpO2 and pulse rate. The NBM-200 includes a reusable ring-shaped sensor probe that fits on the patient's finger, and ...
What is the current status of trial NCT05217576?
This trial is currently completed. It is a NA study. The enrollment target is 387 participants. The study started on 2018-09-21. Estimated completion is 2018-11-02.
What conditions does trial NCT05217576 study?
This clinical trial studies the following conditions: Hemoglobin H.
What interventions are being tested in trial NCT05217576?
The interventions under investigation include: NBM-200 (DEVICE).
Who is sponsoring clinical trial NCT05217576?
This trial is sponsored by OneBlood, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05217576 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05217576's enrollment target sits among peer trials
387 271st of 2000 higher than 1,730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03761108 · 387 participants · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- NCT06917079 · 387 participants · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI